Related News
Home 禄 Business 禄 Manufacturing
Currency losses bite into profit at Novartis
Source: Agencies |
April 24, 2009, Friday
|
Print Edition
Print Edition
PHARMACEUTICALS maker Novartis AG reported a 14-percent decline in first-quarter net income yesterday in part because of currency losses and financing the takeover of the Alcon eye care company.
Novartis posted a profit of US$1.98 billion, compared with US$2.3 billion in the first quarter of 2008.
Novartis said pharmaceuticals led the group's health-care portfolio in the first quarter of 2009 with recently launched products rejuvenating the portfolio.
It cited the first regulatory approval of the drug Afinitor against kidney cancer in the United States and the approval in Europe and the US of the new Ixiaro vaccine against Japanese encephalitis.
"New products fueled ongoing momentum in pharmaceuticals," said Chief Executive Daniel Vasella. "The fundamentals of the business remain positive."
He said the company would be spurred by "the uncertain economy and currency market volatility" to enhance productivity and manage costs.
"Our aim in 2009 remains to again deliver record underlying net sales and earnings excluding currency effects," Vasella said.
Novartis said it recorded net sales for the first three months of the year of US$9.7 billion, down 2 percent from US$9.9 billion in the same period of last year.
Novartis posted a profit of US$1.98 billion, compared with US$2.3 billion in the first quarter of 2008.
Novartis said pharmaceuticals led the group's health-care portfolio in the first quarter of 2009 with recently launched products rejuvenating the portfolio.
It cited the first regulatory approval of the drug Afinitor against kidney cancer in the United States and the approval in Europe and the US of the new Ixiaro vaccine against Japanese encephalitis.
"New products fueled ongoing momentum in pharmaceuticals," said Chief Executive Daniel Vasella. "The fundamentals of the business remain positive."
He said the company would be spurred by "the uncertain economy and currency market volatility" to enhance productivity and manage costs.
"Our aim in 2009 remains to again deliver record underlying net sales and earnings excluding currency effects," Vasella said.
Novartis said it recorded net sales for the first three months of the year of US$9.7 billion, down 2 percent from US$9.9 billion in the same period of last year.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
